GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is known to suppress glucagon secretion, but the mechanism by which GLP-1 exerts this effect is unclear. In this study, we demonstrated GLP-1 receptor (GLP-1R) expression in α-cells using both antibody-dependent and antibody-independent strategies. A novel α-cell–specific GLP-1R knockout (αGLP-1R−/−) mouse model was created and used to investigate its effects on glucagon secretion and glucose metabolism. Male and female αGLP-1R−/− mice both showed higher nonfasting glucagon levels than their wild-type littermates, whereas insulin and GLP-1 levels remained similar. Female αGLP-1R−/− mice exhibited mild glucose intolerance after an intraperitoneal glucose administration and showed increased glucagon secretion in response to a glucose injection compared with the wild-type animals. Furthermore, using isolated islets, we confirmed that αGLP-1R deletion did not interfere with β-cell function but affected glucagon secretion in a glucose-dependent bidirectional manner: the αGLP-1R−/− islets failed to inhibit glucagon secretion at high glucose and failed to stimulate glucagon secretion at very low glucose condition. More interestingly, the same phenomenon was recapitulated in vivo under hypoglycemic and postprandial (fed) conditions. Taken together, this study demonstrates that GLP-1 (via GLP-1R in α-cells) plays a bidirectional role, either stimulatory or inhibitory, in glucagon secretion depending on glucose levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 also inhibits glucagon release from α-cells, which is beneficial for reducing blood glucose levels since glucagon promotes hepatic gluconeogenesis.131,225”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research indicates that the expression level of GLP-1R on α-cells is relatively low.131”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages
Herrera, P. L. (2000) · Development · doi:10.1242/dev.127.11.2317 · Cited by 672
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581 · cited 1×
“Under normal conditions, glucagon secretion is highly responsive to glucose variations: glucagon secretion is minimal when the glucose level is 6–10 mmol/L, increases when glucose is 3–6 mmol/L, and is maximally stimulated when glucose is 2–3 mmol/L (31).”
BackgroundRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 4×
“The controversy on GLP-1R expression in a-cells was largely attributable to the use of different antibodies or different methods (7,8,10,30).”
BackgroundMethodInfluentialNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
ØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396 · cited 1×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 3×
“To make the topic even more complicated, studies have reported that the commonly used anti–GLP1R antibodies are neither specific nor sensitive enough to reliably detect GLP-1R expression in tissues (1,12).”
BackgroundCreutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330 · cited 2×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundResultIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · cited 4×
“To make the topic even more complicated, studies have reported that the commonly used anti–GLP1R antibodies are neither specific nor sensitive enough to reliably detect GLP-1R expression in tissues (1,12).”
BackgroundInfluentialAlpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271 · cited 1×
“Numerous studies have demonstrated that GLP-1 is a potent and physiological inhibitor of glucagon secretion (5,6).”
BackgroundParacrinology of islets and the paracrinopathy of diabetes
Unger, R. H., & Orci, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006639107 · Cited by 269 · cited 1×
“insulin—GLP-1 stimulates insulin secretion from b-cells, which subsequently suppress glucagon secretion because insulin is a powerful inhibitor of glucagon secretion (13,14).”
BackgroundDe Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257 · cited 1×
“Some studies show no GLP-1R protein or mRNA expression in a-cells of normal mice (7), some show GLP-1R is expressed in a small portion of a-cells in adult mice (8,9), and others show clear GLP-1R expression in a-cells, especially during early development and throughout life in mice with a-cell hyperplasia (10,11).”
BackgroundExpression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas
Tornehave, D., Kristensen, P., Rømer, J., Knudsen, L. B., & Heller, R. S. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951319 · Cited by 248 · cited 2×
“The controversy on GLP-1R expression in a-cells was largely attributable to the use of different antibodies or different methods (7,8,10,30).”
BackgroundMethodThe Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice
Chambers, A. P., Sorrell, J. E., Haller, A., Roelofs, K., Hutch, C. R., Kim, K.-S., Gutierrez-Aguilar, R., Li, B., Drucker, D. J., D’Alessio, D. A., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.02.008 · Cited by 241 · cited 2×
“This can be explained by an emerging concept involving intraislet GLP-1 (4,28,29,39).”
BackgroundGlucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass
Solloway, M. J., Madjidi, A., Gu, C., Eastham-Anderson, J., Clarke, H. J., Kljavin, N., Zavala-Solorio, J., Kates, L., Friedman, B., Brauer, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.034 · Cited by 194
(2011) · PubMed · Cited by 187
Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis
Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes · doi:10.2337/db16-0994 · Cited by 187 · cited 2×
“On the other hand, glucagon elevation may have other physiological effects in addition to glucose metabolism, such as amino acid metabolism (40).”
BackgroundHeller, R. S., Kieffer, T. J., & Habener, J. F. (1997) · Diabetes · doi:10.2337/diab.46.5.785 · Cited by 179 · cited 1×
“The controversy on GLP-1R expression in a-cells was largely attributable to the use of different antibodies or different methods (7,8,10,30).”
MethodNavarro, G., Xu, W., Jacobson, D. A., Wicksteed, B., Allard, C., Zhang, G., De Gendt, K., Kim, S. H., Wu, H., Zhang, H., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.015 · Cited by 171 · cited 2×
“In addition, the male hormone testosterone has been shown to activate an extranuclear androgen receptor in b-cells and increase cellular cAMP that subsequently amplifies the incretin effect of GLP-1 (39).”
BackgroundSelf-citationSmith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.005 · Cited by 164 · cited 3×
“The effects of GLP-1 on b-cells are mediated by the GLP-1 receptor (GLP1R), which activates various pathways to promote insulin secretion and b-cell survival (3,4).”
BackgroundResultThe Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154 · cited 1×
“Detection of GLP-1R Expression in Pancreatic a-Cells Using a Specific Anti–GLP-1R Antibody Recent studies revealed that the anti–GLP-1R antibodies from major commercial sources were not specific or not sensitive enough (1,12,24).”
BackgroundDavis, S. N., Galassetti, P., Wasserman, D. H., & Tate, D. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6328 · Cited by 152
Lu, J., Herrera, P. L., Carreira, C., Bonnavion, R., Seigne, C., Calender, A., Bertolino, P., & Zhang, C. X. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.046 · Cited by 146 · cited 1×
“Because previous studies have observed low recombination efficiency mediated by glucagon-cre in some mouse models (25,26), we examined the efficiency of glucagon-cre–mediated GLP-1R ablation in our system.”
BackgroundRegulation of glucagon secretion by incretins
Holst, J. J., Christensen, M., Lund, A., de Heer, J., Svendsen, B., Kielgast, U., & Knop, F. K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01452.x · Cited by 144 · cited 2×
“Numerous studies have demonstrated that GLP-1 is a potent and physiological inhibitor of glucagon secretion (5,6).”
BackgroundGender differences in counterregulation to hypoglycaemia
Amiel, S. A., Maran, A., Powrie, J. K., Umpleby, A. M., & Macdonald, I. A. (1993) · Diabetologia · doi:10.1007/bf00402284 · Cited by 113
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Pancreatic α-Cell Specific Deletion of Mouse Arx Leads to α-Cell Identity Loss
Wilcox, C. L., Terry, N. A., Walp, E. R., Lee, R. A., & May, C. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066214 · Cited by 89 · cited 1×
“Because previous studies have observed low recombination efficiency mediated by glucagon-cre in some mouse models (25,26), we examined the efficiency of glucagon-cre–mediated GLP-1R ablation in our system.”
BackgroundDavis, S. N., Shavers, C., & Costa, F. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e1054 · Cited by 86
Mauvais-Jarvis, F., Virkamaki, A., Michael, M. D., Winnay, J. N., Zisman, A., Kulkarni, R. N., & Kahn, C. R. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2126 · Cited by 83
Self-citationLee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
Schroner, Z., Javorsky, M., Tkacova, R., Klimcakova, L., Dobrikova, M., Habalova, V., Kozarova, M., Zidzik, J., Rudikova, M., & Tkac, I. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01324.x · Cited by 77
Zhang, Y., Fava, G. E., Wang, H., Mauvais‐Jarvis, F., Fonseca, V. A., & Wu, H. (2015) · Molecular Therapy · doi:10.1038/mt.2015.181 · Cited by 63 · cited 1×
“Glucose Tolerance Tests The intraperitoneal glucose tolerance test (ipGTT) was performed essentially as described previously (22).”
MethodSelf-citationJun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60 · cited 2×
“For Glp1r-LoxPmice, we used the novel hGLP-1R mouse model (19,20).”
MethodSelf-citationZhang, Y., Zhang, Y., Bone, R. N., Cui, W., Peng, J.-B., Siegal, G. P., Wang, H., & Wu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036675 · Cited by 56 · cited 1×
“Immunohistochemistry The mouse paraffin-embedded tissue slices were processed for immunohistochemistry (IHC) staining as described previously (23).”
MethodSelf-citationGLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Kielgast, U., Asmar, M., Madsbad, S., & Holst, J. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2440 · Cited by 51 · cited 6×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundResultInfluentialIntra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45 · cited 2×
“This can be explained by an emerging concept involving intraislet GLP-1 (4,28,29,39).”
BackgroundSelf-citationKedees, M. H., Grigoryan, M., Guz, Y., & Teitelman, G. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.024 · Cited by 44 · cited 2×
“The controversy on GLP-1R expression in a-cells was largely attributable to the use of different antibodies or different methods (7,8,10,30).”
BackgroundMethodThe complexity of signalling mediated by the glucagon-like peptide-1 receptor
Fletcher, M. M., Halls, M. L., Christopoulos, A., Sexton, P. M., & Wootten, D. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150244 · Cited by 39 · cited 1×
“The effects of GLP-1 on b-cells are mediated by the GLP-1 receptor (GLP1R), which activates various pathways to promote insulin secretion and b-cell survival (3,4).”
BackgroundPiro, S., Mascali, L. G., Urbano, F., Filippello, A., Malaguarnera, R., Calanna, S., Rabuazzo, A. M., & Purrello, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090093 · Cited by 37 · cited 1×
“Some studies show no GLP-1R protein or mRNA expression in a-cells of normal mice (7), some show GLP-1R is expressed in a small portion of a-cells in adult mice (8,9), and others show clear GLP-1R expression in a-cells, especially during early development and throughout life in mice with a-cell hyperplasia (10,11).”
BackgroundJun, L. S., Showalter, A. D., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 32 · cited 2×
“For Glp1r-LoxPmice, we used the novel hGLP-1R mouse model (19,20).”
MethodSelf-citationGuenifi, A., Ahr�n, B., & Abdel‐Halim, S. M. (2001) · Pancreas · doi:10.1097/00006676-200101000-00010 · Cited by 17 · cited 3×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundResultTaking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
D’Alessio, D. A. (2010) · Diabetes · doi:10.2337/db10-0299 · Cited by 10 · cited 1×
“insulin—GLP-1 stimulates insulin secretion from b-cells, which subsequently suppress glucagon secretion because insulin is a powerful inhibitor of glucagon secretion (13,14).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“131,225 GLP-1 ’ s action on α -cells regulates glucagon release.”
BackgroundInfluentialRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“13 reporter mouse line, detected GLP-1R throughout the -cell and α-cell cytoplasm (45).”
BackgroundIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“Regulation of glucagon secretion by pancreatic α -cells β cells whilst increasing insulin biosynthesis and pancreatic β cell proliferation, in a glucose-dependent manner, are additional effects of this drug class shown in rodents (Zhang et al., 2019).”
Background
Metadata
- Authors
- Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., Sloop, K. W., & Wu, H.
- Affiliations
- Tulane University (US)
- Medical University of South Carolina (US)
- Section of Endocrinology, Department of Medicine, Tulane University Health Science Center, New Orleans, LA
- Eli Lilly (United States) (US)
- Corresponding author
- Wu, Hongju
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-11-02
- Volume
- 68
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6302540
- OpenAlex
- W2899183711
- Semantic Scholar
- ac8cb7167621574489ce0bd5c237f46e94084811
- Cited by
- 104
- References
- 43
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 17 · 2023: 15 · 2022: 5 · 2021: 16 · 2020: 14 · 2019: 7
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Susan Harling Robinson Fellowship in Diabetes research
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-081463, DK-107412, R01-DK-074970, DK-107444)
- U.S. Department of Veterans Affairs VA Merit Review Award (BX003725)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor, glucagon secretion, alpha cells, bidirectional regulation, impaired glucose tolerance, hypoglycemia, islet function, beta-cell function, glucose metabolism
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Female, Flow Cytometry, Glucagon, Glucose, Glucose Tolerance Test, Immunohistochemistry, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Glucagon-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.